Eli Lilly and Company (NYSE:LLY) Trading Down 2.6% – Time to Sell?

Eli Lilly and Company (NYSE:LLY) was down 2.6% on Thursday . The stock traded as low as $1,243.23 and last traded at $1,246.89. Approximately 2,317,653 shares were traded during mid-day trading, a decline of 25% from the average session volume of 3,107,601 shares. The stock had previously closed at $1,280.34.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Obesity-drug leadership remains the main catalyst. Recent coverage says Lilly’s GLP-1 portfolio is outpacing Novo Nordisk’s in the latest quarter, while demand for its obesity treatments remains strong. Investors are also focused on oral GLP-1 candidates and retatrutide, which could expand Lilly’s addressable market. How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
• Positive Sentiment: Pipeline activity continues across multiple therapeutic areas. Lilly reported progress in early-stage studies for LY4178256, eloralintide, lepodisiran and oral candidate LY4065967. Completion of a Phase 3 lebrikizumab trial also supports a potential growth opportunity in atopic dermatitis, although most updates remain too early to affect near-term earnings. Lilly’s Lebrikizumab Trial Completion Signals New Growth Path
• Positive Sentiment: Fundamentals remain supportive. Lilly’s latest quarter exceeded expectations, with revenue rising 47.7% year over year, reinforcing the investment case for continued GLP-1-driven growth. Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?
• Neutral Sentiment: Manufacturing investment is advancing. Lilly disclosed construction and traffic-management plans for its Lehigh Valley project, indicating progress on capacity expansion but no immediate change to earnings expectations. Eli Lilly Reveals Lehigh Valley Construction Plans
• Negative Sentiment: Valuation and competitive risk may be driving profit-taking. After a sharp post-earnings rally and record highs, Lilly trades at a demanding earnings multiple. Investors must also assess Novo Nordisk’s lead in oral obesity treatments and the potential entry of additional competitors.
• Negative Sentiment: Insider selling adds a modest sentiment headwind. EVP Patrik Jonsson sold 6,500 shares for about $7.6 million, though the transaction was executed under a pre-arranged Rule 10b5-1 plan, limiting its bearish significance. SEC Insider Transaction Filing

Analysts Set New Price Targets

Several equities research analysts recently commented on LLY shares. Royal Bank Of Canada raised their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a report on Wednesday, July 8th. Weiss Ratings lowered shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 11th. Barclays boosted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 15th. Finally, Bank of America lifted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company Trading Down 2.6%

The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The business has a 50 day simple moving average of $1,176.04 and a two-hundred day simple moving average of $1,056.96. The stock has a market cap of $1.17 trillion, a price-to-earnings ratio of 41.84, a price-to-earnings-growth ratio of 1.45 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.Eli Lilly and Company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is 23.22%.

Insiders Place Their Bets

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last ninety days. Corporate insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Willner & Heller LLC lifted its stake in Eli Lilly and Company by 1.0% during the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after purchasing an additional 9 shares during the last quarter. Aspiring Ventures LLC increased its stake in Eli Lilly and Company by 3.7% during the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after purchasing an additional 9 shares during the last quarter. Wealthspan Partners LLC raised its holdings in shares of Eli Lilly and Company by 0.4% during the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock worth $2,543,000 after purchasing an additional 9 shares during the period. Navigoe LLC raised its holdings in shares of Eli Lilly and Company by 8.7% during the second quarter. Navigoe LLC now owns 113 shares of the company’s stock worth $135,000 after purchasing an additional 9 shares during the period. Finally, Tanager Wealth Management LLP lifted its position in shares of Eli Lilly and Company by 2.6% in the 4th quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after buying an additional 10 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.